Abstract
Background: Granulomatosis with polyangiitis (GPA) patients are prone to disease relapses. We aimed to determine whether GPA patients at risk for relapse can be identified by differences in B cell subset frequencies.
Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1-6.3). Circulating B cell subset frequencies were analyzed by flow cytometry determining the expression of CD19, CD38, and CD27. B cell subset frequencies at the time of inclusion of future-relapsing (F-R) and non-relapsing (N-R) patients were compared and related to relapse-free survival. Additionally, CD27(+)CD38(hi) B cells were assessed in urine and kidney biopsies from active anti-neutrophil cytoplasmic autoantibody-associated vasculitides (AAV) patients with renal involvement.
Results: Within 1.6 years, 30% of patients experienced a relapse. The CD27(+)CD38(hi) B cell frequency at the time of inclusion was increased in F-R (median: 2.39%) compared to N-R patients (median: 1.03%; p = 0.0025) and a trend was found compared with the HCs (median: 1.33%; p = 0.08). This increased CD27(+)CD38(hi) B cell frequency at inclusion was correlated to decreased relapse-free survival in GPA patients. In addition, 74.7% of patients with an increased CD27(+)CD38(hi) B cell frequency (>= 2.39%) relapsed during follow-up compared to 19.7% of patients with a CD27(+)CD38(hi) B cell frequency of
Conclusions: Our data suggests that having an increased frequency of circulating CD27(+)CD38(hi) B cells during remission is related to a higher relapse risk in GPA patients, and thereforemight be a potentialmarker to identify those GPA patients at risk for relapse.
Original language | English |
---|---|
Article number | 2221 |
Number of pages | 10 |
Journal | Frontiers in Immunology |
Volume | 10 |
DOIs | |
Publication status | Published - 24-Sept-2019 |
Keywords
- vasculitis
- granulomatosis with polyangiitis
- ANCA
- B cells
- relapse
- CYTOPLASMIC AUTOANTIBODIES
- WEGENERS-GRANULOMATOSIS
- PLASMA-CELLS
- VASCULITIS
- CYCLOPHOSPHAMIDE
- DIFFERENTIATION
- SPECIFICITY
- ACTIVATION
- RITUXIMAB
- PROTEIN